FAST NEWS: Connect Biopharma Plunges on Poor Results for Colitis Drug
The latest: Connect Biopharma (CNTB.US) said late on Tuesday that results from a Phase 2 trial for its CBP-307 drug for treatment of patients with moderate to severe ulcerative colitis…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
-
Everest reaches new heights on growing drug sales
1952.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
- TransThera seeks Hong Kong IPO to sustain cancer drug research
